Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Total Current Liabilities: 2009-2025

Historic Total Current Liabilities for Aytu Biopharma (AYTU) over the last 17 years, with Jun 2025 value amounting to $63.1 million.

  • Aytu Biopharma's Total Current Liabilities rose 7.74% to $66.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.0 million, marking a year-over-year increase of 7.74%. This contributed to the annual value of $63.1 million for FY2025, which is 1.34% up from last year.
  • Aytu Biopharma's Total Current Liabilities amounted to $63.1 million in FY2025, which was up 1.34% from $62.2 million recorded in FY2024.
  • In the past 5 years, Aytu Biopharma's Total Current Liabilities ranged from a high of $109.4 million in FY2021 and a low of $62.2 million during FY2024.
  • In the last 3 years, Aytu Biopharma's Total Current Liabilities had a median value of $63.1 million in 2025 and averaged $64.8 million.
  • Per our database at Business Quant, Aytu Biopharma's Total Current Liabilities surged by 280.48% in 2021 and then tumbled by 41.12% in 2022.
  • Aytu Biopharma's Total Current Liabilities (Yearly) stood at $109.4 million in 2021, then tumbled by 41.12% to $64.4 million in 2022, then climbed by 7.10% to $69.0 million in 2023, then decreased by 9.83% to $62.2 million in 2024, then grew by 1.34% to $63.1 million in 2025.